Cover Image
Market Research Report

Transdermal Hormone Replacement: Products, Players, Markets and Forecasts

Published by Greystone Research Associates Product code 242714
Published Content info
Delivery time: 1-2 business days
Back to Top
Transdermal Hormone Replacement: Products, Players, Markets and Forecasts
Published: June 1, 2012 Content info:

Greystone Research Associates is pleased to announce the publication of a new market study. Transdermal Hormone Replacement: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug developers, device packaging designers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for therapeutic hormones administered transdermally. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

The Evolving Landscape for Hormone Replacement

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of decreasing hormone levels have come to the forefront as a quality-of-life issue for patients and their families. For the past two decades, the healthcare industry has responded to this clinical need by developing, testing and marketing hormone replacement therapy (HRT) products. Because of their ease-of-use and dosing characteristics, drug developers are continuing to turn to transdermal delivery systems for HRT products. There are more than 40 million post-menopausal women in the United States alone, and this group is expected to grow by 50% by 2020. With the aging of the population worldwide, conditions and diseases such as menopause, osteoporosis and heart disease, which may benefit from hormone replacement therapy, are expected to become significantly more prevalent. The industry continues to attract interest in the form of new participants and products. While the global market continues to be dominated by the FDA-approved HRT products of major pharmaceutical firms, regional markets are a bit more competitive, and present unique challenges to transdermal HRT sector participants.


  • Analyzes and evaluates the global market opportunity for transdermal hormone replacement and assesses the probable impact of evolving regulatory, economic and demand factors
  • Assesses transdermal products approved or in development for the delivery of therapeutic hormones
  • Provides detailed descriptions of hormone replacement treatment segments, market factors, and business strategies
  • Forecasts transdermal hormone replacement product demand to 2016 by geographic region and product segment
  • Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners


Research methodology is based on primary research in the form of in-depth interviews with key market participants, technology developers, distributors, industry experts, and market influencers, a list that includes regulatory officials, industry trade groups, and materials standards organizations.

Primary data is evaluated and normalized against secondary sources including trade journal articles, technical literature, industry publications, company data sheets and published information, and statistical data from government agencies and trade associations.

Forecasts and projections of market demand and future market activity are derived using standard modeling and statistical techniques.

Table of Contents
Product Code: THR672V

Table of Contents

Executive Summary

  • Scope and Definitions
  • The Hormone Replacement Therapy Market
  • The Opportunity for Transdermal Hormone Replacement Therapy

The Hormone Replacement Therapy Market Opportunity

  • Evolution in HRT Guidelines
  • Regional Factors in HRT Practice
  • Hormone Replacement Therapy Demand Drivers
  • Competitive Landscape
  • Factors Limiting Growth

Transdermal Drug Delivery Dynamics

  • Transdermal HRT Patches
    • Patch Designs and Construction
    • Transdermal Patch Manufacturing and Packaging
    • The Patch Manufacturing Ecosystem
    • Patch Economics
  • Transdermal HRT Gels
    • Transdermal Formulations
    • IP and Proprietary Technology
    • Limitations of Topical Gels & Emulsions
  • Transdermal HRT Sprays

Transdermal HRT Indications and Markets

  • Hypoestrogenism
  • Hypogonadism
  • Menopause
    • Vasomotor Symptoms
    • Vaginal Atrophy
  • Postmenopausal Osteoporosis

Transdermal HRT Product Assessments and Market Prospects

  • Approved Transdermal HRT Products
  • Estradiol
    • Ascend
    • Azur
    • Bayer Healthcare
    • Graceway
    • KV Pharm
    • Mylan
    • Novartis
    • Watson Laboratories
    • Upsher-Smith
    • Faran SA
    • Janssen-Cilag
    • Meda
    • Shiseido
    • Solvay
  • Estradiol Levonorgestrel
    • Bayer Healthcare,
  • Estradiol/Norethindrone
    • Novartis
  • Testosterone
    • Abbott Labs
    • Auxilium
    • Endo Pharms
    • Teva
    • Watson Laboratories
  • Development-Stage Transdermal HRT Products
    • Estrogen
    • Testosterone
    • Other Hormones

Transdermal Hormone Replacement Market Factors

  • Regional Regulations
  • Clinical Trials
  • Quality and Reliability
  • Indications Prescribing Guidelines and Off-Label Prescribing
  • Managed Care and Payor Initiatives
  • Rx-to-OTC Switching

Market Forecasts

  • Forecast Methodology
  • Forecasts by Region
  • Forecasts by Drug Class
  • Forecasts by Delivery Form Factor
  • Market Share Data

Company Profiles

Back to Top